Clinical Trial Update: Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating adjuvant interleukin-2 (Proleukin) combined with dacarbazine (DTIC) in high-risk metastatic melanoma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: University of Louisville | Conditions: Metastatic Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING